Online citations, reference lists, and bibliographies.
← Back to Search

Structures Of Purine Nucleosidase From Trypanosoma Brucei Bound To Isozyme-specific Trypanocidals And A Novel Metalorganic Inhibitor.

F. Giannese, M. Berg, P. Van der Veken, V. Castagna, P. Tornaghi, K. Augustyns, M. Degano
Published 2013 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Sleeping sickness is a deadly disease that primarily affects sub-Saharan Africa and is caused by protozoan parasites of the Trypanosoma genus. Trypanosomes are purine auxotrophs and their uptake pathway has long been appreciated as an attractive target for drug design. Recently, one tight-binding competitive inhibitor of the trypanosomal purine-specific nucleoside hydrolase (IAGNH) showed remarkable trypanocidal activity in a murine model of infection. Here, the enzymatic characterization of T. brucei brucei IAGNH is presented, together with its high-resolution structures in the unliganded form and in complexes with different inhibitors, including the trypanocidal compound UAMC-00363. A description of the crucial contacts that account for the high-affinity inhibition of IAGNH by iminoribitol-based compounds is provided and the molecular mechanism underlying the conformational change necessary for enzymatic catalysis is identified. It is demonstrated for the first time that metalorganic complexes can compete for binding at the active site of nucleoside hydrolase enzymes, mimicking the positively charged transition state of the enzymatic reaction. Moreover, we show that divalent metal ions can act as noncompetitive IAGNH inhibitors, stabilizing a nonproductive conformation of the catalytic loop. These results open a path for rational improvement of the potency and the selectivity of existing compounds and suggest new scaffolds that may be used as blueprints for the design of novel antitrypanosomal compounds.
This paper references
10.1107/S0907444910007493
Features and development of Coot
P. Emsley (2010)
Control and Surveillance of African Trypanosomiasis. Geneva: World Health Organization
(1998)
Markell and Voge's medical parasitology
D. T. John (1999)
10.2174/092986710791556023
Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?
M. Berg (2010)
10.1107/S0907444904019158
Coot: model-building tools for molecular graphics.
P. Emsley (2004)
10.1371/journal.pntd.0000506
Adenosine Kinase of T. b. rhodesiense Identified as the Putative Target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine Using Chemical Proteomics
S. Kuettel (2009)
10.1016/S0925-4439(02)00073-X
Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
V. Schramm (2002)
10.1016/J.JMB.2004.02.049
Leaving group activation by aromatic stacking: an alternative to general acid catalysis.
W. Versées (2004)
10.1021/ja805555a
Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes.
J. Maksimoska (2008)
10.1017/S0031182000056110
Uptake of purine bases and nucleosides in African trypanosomes.
D. M. James (1980)
10.1016/S0035-9203(99)90151-7
Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
D. Legros (1999)
10.1182/BLOOD-2005-03-1309
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
V. Gandhi (2005)
Guanosine-inosine-preferring nucleoside N-glycohydrolase from Crithidia fasciculata.
B. Estupiñán (1994)
10.1021/BI990829U
Iminoribitol transition state analogue inhibitors of protozoan nucleoside hydrolases.
R. W. Miles (1999)
10.1021/ja107640u
Energy landscapes associated with macromolecular conformational changes from endpoint structures.
A. Fornili (2010)
10.1021/IC50002A043
Copper(II) Ion and Nickel(II) Ion Complexes with 2-Amino-2-(hydroxymethyl)-1,3-propanediol. Reactions with Sodium Hydroxide
J. L. Hall (1962)
10.1021/BI973012E
Trypanosomal nucleoside hydrolase. A novel mechanism from the structure with a transition-state inhibitor.
M. Degano (1998)
10.1107/S0907444910045749
Overview of the CCP4 suite and current developments
M. Winn (2011)
Purine nucleosidase
Giannese
Antimicrob
M. Berg (2010)
10.2217/fmb.11.44
Development of novel drugs for human African trypanosomiasis.
R. Brun (2011)
10.1021/bi702448s
Structural basis for substrate specificity in group I nucleoside hydrolases.
E. Iovane (2008)
10.1016/J.STR.2004.03.018
Crystal structure to 1.7 a of the Escherichia coli pyrimidine nucleoside hydrolase YeiK, a novel candidate for cancer gene therapy.
B. Giabbai (2004)
Biochemistry 38, 13147-13154
L.V. (1999)
10.1107/S0907444997005696
wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models.
A. Perrakis (1997)
10.1111/J.1432-1033.1979.TB12921.X
Metal Ion/Buffer Interactions
B. E. Fischer (1979)
10.1177/001452469000101110
"J."
G.G. Stokes (1890)
Acta Cryst
J.E. (1999)
10.1016/J.SBI.2003.10.002
Catalysis by nucleoside hydrolases.
W. Versées (2003)
10.1371/journal.pone.0026916
Plasmodium falciparum Parasites Are Killed by a Transition State Analogue of Purine Nucleoside Phosphorylase in a Primate Animal Model
M. Cassera (2011)
10.1016/j.bmc.2008.05.056
N-Arylmethyl substituted iminoribitol derivatives as inhibitors of a purine specific nucleoside hydrolase.
A. Goeminne (2008)
10.1371/journal.pntd.0000658
The Genome Sequence of Trypanosoma brucei gambiense, Causative Agent of Chronic Human African Trypanosomiasis
A. Jackson (2010)
10.1016/J.JMB.2006.03.026
Transition-state complex of the purine-specific nucleoside hydrolase of T. vivax: enzyme conformational changes and implications for catalysis.
W. Versées (2006)
10.1016/S0140-6736(75)91950-9
NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY
EloiseR. Giblett (1975)
10.1016/J.FEMSRE.2005.03.004
Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy.
H. D. de Koning (2005)
10.1016/0022-2836(71)90324-X
The interpretation of protein structures: estimation of static accessibility.
B. Lee (1971)
10.1038/214906A0
Metal Complexing by Tris Buffer
D. Allen (1967)
10.1021/BI952998U
Inosine-uridine nucleoside hydrolase from Crithidia fasciculata. Genetic characterization, crystallization, and identification of histidine 241 as a catalytic site residue.
D. N. Gopaul (1996)
10.1016/j.bbapap.2009.02.011
Crystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitors.
W. Versées (2009)
10.1126/SCIENCE.1112642
The Genome of the African Trypanosome Trypanosoma brucei
M. Berriman (2005)
Enzymes of the human erythrocyte. II. Purine nucleoside phosphorylase; specific properties.
K. Tsuboi (1957)
Acta Cryst
W. Kabsch (2010)
10.1016/S0966-842X(98)01433-4
Recent advances in identifying and validating drug targets in trypanosomes and leishmanias.
M. Barrett (1999)
10.1016/s0021-9258(18)54759-1
Nucleoside hydrolase from Crithidia fasciculata. Metabolic role, purification, specificity, and kinetic mechanism.
D. W. Parkin (1991)
10.1021/bi100697d
Structure and mechanism of the 6-oxopurine nucleosidase from Trypanosoma brucei brucei.
An Vandemeulebroucke (2010)
Biochim
V. L. Schramm (2002)
10.1107/S0567739478001114
On the treatment of negative intensity observations
S. French (1978)
10.1016/0166-6851(81)90049-9
Purine metabolism in Trypanosoma cruzi.
R. Berens (1981)
10.1021/BI962319V
Isozyme-specific transition state inhibitors for the trypanosomal nucleoside hydrolases.
D. W. Parkin (1997)
10.1107/S0907444911001314
REFMAC5 for the refinement of macromolecular crystal structures
G. Murshudov (2011)
10.1021/JA953537Z
Mechanistic Diagnoses of N-Ribohydrolases and Purine Nucleoside Phosphorylase
L. Mazzella (1996)
10.1107/S0907444907047580
ARP/wARP and molecular replacement: the next generation
S. Cohen (2008)
10.1021/BI952999M
Three-dimensional structure of the inosine-uridine nucleoside N-ribohydrolase from Crithidia fasciculata.
M. Degano (1996)
Biochemistry, 49, 8999–9010
M. (2010)
10.1074/JBC.271.36.21713
Purine-specific Nucleoside N-Ribohydrolase from Trypanosoma brucei brucei
D. W. Parkin (1996)
10.1006/JMBI.2001.4548
Structure and function of a novel purine specific nucleoside hydrolase from Trypanosoma vivax.
W. Versées (2001)
10.1016/0166-6851(84)90117-8
Purine and pyrimidine metabolism in the Trypanosomatidae.
D. Hammond (1984)
10.1080/00034983.1985.11811883
Adenosine cycle in African trypanosomes.
P. O. Ogbunude (1985)
10.1021/BI00089A007
Correlation of the molecular electrostatic potential surface of an enzymatic transition state with novel transition-state inhibitors.
B. Horenstein (1993)
Biochemistry, 36, 3528–3534
V. L. Schramm (1997)
10.1371/journal.pntd.0001164
Crystal Structures of T. b. rhodesiense Adenosine Kinase Complexed with Inhibitor and Activator: Implications for Catalysis and Hyperactivation
S. Kuettel (2011)
10.1107/S0907444909042073
MolProbity: all-atom structure validation for macromolecular crystallography
Vincent B. Chen (2010)
10.1107/S0907444909042589
Molecular replacement with MOLREP.
A. Vagin (2010)
10.1128/AAC.01787-09
Evaluation of Nucleoside Hydrolase Inhibitors for Treatment of African Trypanosomiasis
M. Berg (2010)
10.1107/S0907444909047374
Integration, scaling, space-group assignment and post-refinement
W. Kabsch (2010)
10.1074/jbc.M705603200
Adenosine Kinase Mediates High Affinity Adenosine Salvage in Trypanosoma brucei*
M. Vodnala (2008)
10.1107/S090744499801405X
Efficient anisotropic refinement of macromolecular structures using FFT.
G. Murshudov (1999)
10.1002/PRO.5560041120
How to measure and predict the molar absorption coefficient of a protein
C. Pace (1995)



This paper is referenced by
10.3390/molecules21101389
The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases—Part III: In-Silico Molecular Docking Investigations
I. V. Ogungbe (2016)
10.1371/journal.pone.0124183
Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro
E. Freitas (2015)
Computational insight into the broad substrate specificity of enzymes that process nucleic acids
S. Lenz (2018)
10.1155/2015/826047
In Silico Investigation of Flavonoids as Potential Trypanosomal Nucleoside Hydrolase Inhibitors
C. Ha (2015)
10.3389/fimmu.2019.00813
Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines
C. B. Palatnik-de-Sousa (2019)
10.1016/j.bbagen.2018.08.015
Cloning and characterisation of the Equilibrative Nucleoside Transporter family of Trypanosoma cruzi: ultra-high affinity and selectivity to survive in the intracellular niche.
G. D. Campagnaro (2018)
10.1155/2020/9130719
In Silico Identification of New Targets for Diagnosis, Vaccine, and Drug Candidates against Trypanosoma cruzi
Rafael Obata Trevisan (2020)
10.1007/s10822-018-0178-y
Structural explanation for the tunable substrate specificity of an E. coli nucleoside hydrolase: insights from molecular dynamics simulations
Stefan A. P. Lenz (2018)
10.1016/j.bioorg.2020.103933
Design, synthesis and antitrypanosomal activity of heteroaryl-based 1,2,4-triazole and 1,3,4-oxadiazole derivatives.
M. S. Shaykoon (2020)
Semantic Scholar Logo Some data provided by SemanticScholar